We send the latest information from SMC Laboratories.
We are pleased to announce that we presented a poster at APASL STC 2025 Tokyo, under Poster ID PF1-5 10244. Ti…
We are pleased to announce our participation in BioJapan 2025, which will be held from October 8th to 10th at …
At our company, we conduct preclinical evaluations using the elastase-induced emphysema (PPE: porcine pancreat…
We have confirmed the renoprotective effect of the SGLT2 inhibitor dapagliflozin (20 mg/kg, oral administratio…
A research article utilizing our bleomycin-induced pulmonary fibrosis (IPF) mouse model has been published in …
In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…
In preclinical drug development for fibrotic lung diseases, the ability to quantitatively and reproducibly ass…
SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachlori…
To better meet evolving research needs, SMC Laboratories has officially launched a lineup of preclinical rat d…
In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland pu…
Featured in Frontiers in Immunology: A Preclinical Package to Maximize the Value of Your MASH Candidate…
SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Societ…